Compound tracker
Ketamine.
A source-backed research page for trial rows and update notes connected to this compound or investigational product. The page is generated from the Notion tracker and should be read as a living research map, not a medical conclusion.
9 trial rows 5 update rows Latest checked: May 12, 2026 All trials Claim boundary
Trial registration, company topline, CNPV/rolling-review status, recruitment status, public-dashboard data, or review literature do not equal approval, label, reimbursement, access, safety, or efficacy. Check each source note before turning a row into a claim.
Backlinks
This page links out to registry/source records, the global trial tracker, the updates feed, and matching wiki dossiers when available.
N/A / Not Applicable / Phase 2 / Phase 4
Phases tracked
Active / Completed / Not yet recruiting
Statuses seen
Trial rows
NCT07099534 Phase 2 Not yet recruiting updated May 12, 2026
- Condition
- Severe borderline personality disorder
- Sponsor / institution
- University Hospital, Toulouse
- Start date
- Sep 1, 2026
Tracker note / source boundary
Last checked: 2026-05-16 20:00 UTC. ClinicalTrials.gov lists NCT07099534 as a not-yet-recruiting Phase 2, single-group/open-label pilot sponsored by University Hospital, Toulouse. Estimated enrollment 38; two IV ketamine 0.5 mg/kg infusions 24 hours apart plus Good Psychiatric Management; primary outcome is BSL-23 symptom-severity change from baseline to Day 9. Claim boundary: registry/watch and psychiatric-ketamine context only; no results, no randomized proof, no FDA approval/label/access/reimbursement claim, no broad safety claim, and not classic-psychedelic efficacy evidence.
NCT07317232 Not Applicable Recruiting updated Jan 5, 2026
- Condition
- Healthy Women Volunteers
- Sponsor / institution
- University of Sao Paulo
- Start date
- Dec 20, 2025
Tracker note / source boundary
ClinicalTrials.gov manual verification on 2026-04-17 | Overall status: RECRUITING | Exact phase: Not Applicable | Lead sponsor: University of Sao Paulo | Conditions: Healthy Women Volunteers | Interventions: Ayahuasca; Esketamine
NCT07317219 Not Applicable Recruiting updated Jan 5, 2026
- Condition
- Healthy Women Volunteers
- Sponsor / institution
- University of Sao Paulo
- Start date
- Dec 20, 2025
Tracker note / source boundary
ClinicalTrials.gov manual verification on 2026-04-17 | Overall status: RECRUITING | Exact phase: Not Applicable | Lead sponsor: University of Sao Paulo | Conditions: Healthy Women Volunteers | Interventions: Ayahuasca; Esketamine
NCT07317206 Phase 2 Recruiting updated Jan 5, 2026
- Condition
- Posttraumatic Stress Disorder (PTSD)
- Sponsor / institution
- University of Sao Paulo
- Start date
- Dec 20, 2025
Tracker note / source boundary
ClinicalTrials.gov manual verification on 2026-04-17 | Overall status: RECRUITING | Exact phase: Phase 2 | Lead sponsor: University of Sao Paulo | Conditions: Posttraumatic Stress Disorder (PTSD) | Interventions: Ayahuasca; Esketamine
NCT07212946 Phase 2 Completed updated Dec 29, 2025
- Condition
- Major Depression Severe
- Sponsor / institution
- University of Sao Paulo
- Start date
- Oct 30, 2022
Tracker note / source boundary
ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: University of Sao Paulo | Official title: Four Doses of Ayahuasca or Esketamine in Major Depressive Disorder: a Double-blind Randomized Trial | Condition: Major Depression Severe | Intervention: Ayahuasca; Esketamine | Study type: Interventional | Comparator intervention also includes esketamine, so this row is tagged to both Ayahuasca and Ketamine.
NCT06668571 Phase 2 Recruiting updated Oct 14, 2025
- Condition
- Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
- Sponsor / institution
- Mayo Clinic
- Start date
- Feb 10, 2025
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Phase 2 | Lead sponsor: Mayo Clinic | Conditions: Depressive Disorder, Treatment-Resistant; Treatment Resistant Depression (TRD)
NCT05809609 N/A Recruiting updated May 21, 2024
- Condition
- Treatment Resistant Depression, Depression, Major Depressive Disorder
- Sponsor / institution
- University of Oxford
- Start date
- Jul 1, 2022
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Not applicable | Lead sponsor: University of Oxford | Conditions: Treatment Resistant Depression; Depression; Major Depressive Disorder
NCT04352621 Phase 4 Active updated Apr 20, 2020
- Condition
- Major Depressive Disorder
- Sponsor / institution
- University of Cincinnati
- Start date
- May 1, 2020
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: UNKNOWN | Exact phase: Phase 4 | Lead sponsor: University of Cincinnati | Conditions: Major Depressive Disorder
NCT02772211 Phase 4 Active updated May 13, 2016
- Condition
- Treatment Resistant Depression
- Sponsor / institution
- Sheba Medical Center
- Start date
- —
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: UNKNOWN | Exact phase: Phase 4 | Lead sponsor: Sheba Medical Center | Conditions: Treatment Resistant Depression
Related updates
May 15, 2026 Publication Research
Last checked: 2026-05-16 20:00 UTC. PubMed abstract describes a Journal of Affective Disorders retrospective cohort of 233 TRD patients receiving esketamine plus dexmedetomidine patient-controlled sleep (PCSL), with follow-up at 1, 3, and 6 months. Abstract reports HAMD/PSQI decreases and response rates of 62.00%, 59.73%, and 58.49%, with no serious adverse events observed during follow-up. Claim boundary: retrospective uncontrolled multimodal clinic-regimen signal only; not randomized proof, not classic psychedelic efficacy evidence, not approval/label/access/reimbursement, not medical advice, and not generalizable safety proof.
Source/tracker note
PubMed PMID 41621446 / DOI 10.1016/j.jad.2026.121311. Abstract: retrospective inclusion of 233 TRD patients; HAMD and PSQI assessed at 1, 3, and 6 months after first esketamine infusion; PCSL and additional esketamine recorded; HAMD/PSQI scores decreased significantly; response rates 62.00%, 59.73%, 58.49%; no serious adverse events observed during follow-up.
May 15, 2026 Publication Research
PubMed PMID 41616859 is a systematic review/meta-analysis of nine observational real-world studies of intranasal esketamine for treatment-resistant depression; abstract reports symptom reduction/remission patterns and pooled adverse-event/dissociation estimates.
Source/tracker note
Last checked 2026-05-16 UTC. Claim boundary: observational real-world evidence synthesis only; not new approval, label expansion, reimbursement/access finding, proof of comparative efficacy, or broad safety guarantee. Abstract itself cautions that observational evidence and absence of control groups mean effect sizes should be interpreted with caution.
May 14, 2026 Publication Research
Last checked: 2026-05-16 16:00 UTC. Journal of Affective Disorders abstract reports a MGH Ketamine Clinic observational/network-analysis study of 447 TRD patients receiving acute-phase IV ketamine or intranasal esketamine. Abstract says pre-treatment symptom-network density was higher in non-responders than responders and frames baseline network density as a potential correlate of ketamine outcomes. Claim boundary: observational clinic/precision-medicine correlate; not psychedelic efficacy evidence, not randomized proof, not approval/access/medical advice.
Source/tracker note
Abstract: “447 patients receiving acute-phase intravenous ketamine or intranasal esketamine at the MGH Ketamine Clinic were included.” “Pre-treatment network density was significantly higher in non-responders ... compared to responders ...” “Pre-treatment network density serves as a potential correlate of treatment outcomes of ketamine for TRD.”
May 1, 2026 Publication Research
Last checked: 2026-05-16 16:00 UTC. British Journal of General Practice narrative review/public-health article describes rising UK ketamine misuse among young people; PubMed lists May 2026. Abstract says deaths increased six-fold over the past decade, ketamine is now the fifth most commonly used drug among young people, and urinary/abdominal presentations can mask dependence or ketamine-related harm. Claim boundary: narrative/public-health signal, not clinical efficacy evidence, not US prevalence, not medical advice, and distinct from regulated ketamine/esketamine treatment contexts.
Source/tracker note
Abstract: “Ketamine ... has become one of the fastest growing substances of misuse in the UK, with deaths increasing six-fold over the past decade.” “It is now the fifth most commonly used drug among young people...” “presentations frequently occur under the guise of urinary or abdominal symptoms.”
Mar 31, 2026 Publication Research
Source/tracker note
Multi-site study (n=150) shows ketamine-induced glutamatergic changes correlate with rapid symptom improvement in treatment-resistant depression.
Conditions touched
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)Healthy Women VolunteersMajor Depression SevereMajor Depressive DisorderPosttraumatic Stress Disorder (PTSD)Severe borderline personality disorderTreatment Resistant DepressionTreatment Resistant Depression, Depression, Major Depressive Disorder